Results 201 to 210 of about 7,855 (246)
Dynamic Regulation of Histone Lysine Methylation by Demethylases
, 2007 Yang Shi, Johnathan R. Whetstine
openalex +1 more source
MedComm – Oncology, Volume 4, Issue 2, June 2025.Cancer stem cells, characterized by self‐renewal, differentiation, heterogeneity, plasticity and tumorigenicity, are regulated by intrinsic factors such as signaling pathways, transcription factors, metabolism and noncoding RNAs, as well as environmental cells (including tumor cells, immune cells and stromal cells), environmental factors and distant ...
Zhenzhen Chen +11 more
wiley +1 more source
Phase Separation: A New Dimension to Understanding Tumor Biology and Therapy
MedComm – Oncology, Volume 4, Issue 2, June 2025.Liquid–liquid phase separation (LLPS) facilitates the assembly of biomolecular condensates by leveraging weak multivalent interactions. The low‐complexity domains, foldable domains of proteins, and nucleic acids provide multivalent interaction sites among different molecules and contribute to the formation of condensates.
Xingwen Wang +4 more
wiley +1 more source
Advanced Science, Volume 12, Issue 17, May 8, 2025.The upregulation of FTO in autoimmune dry eye suppresses the recognition of pri‐miR‐31 by DGCR8, thereby inhibiting the maturation of miR‐31‐5p and reducing its inhibitory effect on the target gene P2RX7. The activation of P2RX7 subsequently triggers the p38 MAPK signaling pathway and increases the level of M1‐related genes, thus exacerbating the ...
Lu Zhao +10 more
wiley +1 more source
STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy
Advanced Science, Volume 12, Issue 17, May 8, 2025.STING agonists show promise in preclinical studies in boosting an anti‐tumor response using the immune system. However, different limitations remain, and future research is needed to better understand how STING activation impacts the tumor microenvironment, identify effective combination strategies, and determine the best tumor types for STING agonist ...
Laura Gehrcken +3 more
wiley +1 more source
Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements
Cancer Medicine, Volume 14, Issue 9, May 2025.ABSTRACT Background Triple‐negative breast cancer (TNBC) is one of the most heterogeneous and menacing forms of breast cancer, with no sustainable cure available in the current treatment landscape. Its lack of targets makes it highly unresponsive to various treatment modalities, which is why chemotherapy continues to be the primary form of treatment ...
Rachana Raman +3 more
wiley +1 more source
Cancer Reports, Volume 8, Issue 5, May 2025.ABSTRACT Background Supposed ‘spontaneous’ remissions in chronic lymphocytic leukaemia (CLL) are extremely rare. By the most stringent immunophenotypic criteria, there are only seven cases to date of unexplained, immune system effected cures. A historic review of this phenomenon is presented as context for this eighth case of CLL immunophenotypic ...
Carmen Wheatley
wiley +1 more source
Clinical Pharmacology in Drug Development, Volume 14, Issue 5, Page 382-390, May 2025.Abstract Dordaviprone (ONC201) is a novel, small molecule imipridone with antitumor effects in glioma patients. This study evaluated the pharmacokinetics and safety of dordaviprone following single escalating doses (Part A), as a capsule content mixed with applesauce or Gatorade (sports drink) [Part B1]), and with or without food [Part B2].
Shamia L. Faison +7 more
wiley +1 more source
TET3 regulates hematopoietic stem cell homeostasis during embryonic and adult hematopoiesis
HemaSphere, Volume 9, Issue 5, May 2025.ABSTRACT The ten‐eleven translocation family of enzymes (TET1/2/3) promotes DNA demethylation and is essential for hematopoiesis. While the roles of TET1 and TET2 are well‐studied in hematopoiesis, the requirement of TET3 in embryonic and adult hematopoiesis is less investigated.
Harmony C. Ketchum +5 more
wiley +1 more source